NEW YORK, Oct. 2, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Progenics Pharmaceuticals, Inc. (PGNX) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Lantheus Holdings, Inc. (LNTH). Stockholders will receive 0.2502 shares of Lantheus Holdings common stock for each share of Progenics Pharmaceuticals stock that they hold. The transaction is valued at approximately $412 million and is expected to close in the first quarter of 2020.
If you are a stockholder of Progenics Pharmaceuticals, Inc. and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/pgnx. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at email@example.com, or by telephone at 914-400-1920 or 844-400-4643 (toll-free).
Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com.
Attorney Advertising. Prior results do not guarantee a similar outcome.